Research programme: cyclin-dependent kinase inhibitors - Amgen
Alternative Names: Compound '277; Cyclin-dependent kinase inhibitors research programme - AmgenLatest Information Update: 05 Sep 2008
At a glance
- Originator Amgen
- Class Small molecules
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 05 Sep 2008 No development reported - Preclinical for Cancer in USA (unspecified route)
- 18 Oct 2004 Preclinical trials in Cancer in USA (unspecified route)